Arrowstreet Capital, Limited Partnership Supernus Pharmaceuticals, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $122 Billion
- Q4 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 174,916 shares of SUPN stock, worth $5.61 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
174,916
Previous 97,523
79.36%
Holding current value
$5.61 Million
Previous $3.04 Million
108.03%
% of portfolio
0.01%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$333 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$197 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$155 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$92.3 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$84.3 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...